Stiripentol's Primary Effect on GABAergic Transmission
Stiripentol enhances GABAergic transmission mainly by inhibiting GABA transporters (GATs), particularly GAT-1, which reduces GABA reuptake into neurons and glial cells. This increases extracellular GABA levels, prolonging and intensifying GABA_A receptor-mediated inhibition in the brain.[1][2]
How It Differs from Direct GABA_A Agonism
Unlike benzodiazepines or barbiturates that directly activate GABAA receptors, stiripentol acts indirectly via allosteric modulation. At low concentrations (1-10 μM), it potentiates GABAA receptors containing α3 subunits, increasing chloride influx and hyperpolarization without causing sedation at therapeutic doses.[3][4] It also weakly inhibits GABA transaminase (GABA-T), further elevating GABA availability.[2]
Role in Epilepsy Treatment
In Dravet syndrome, stiripentol boosts tonic GABAergic currents in dentate gyrus granule cells, suppressing hypersynchronous network activity. Studies in rodent models show it reduces seizure frequency by 50-70% when combined with clobazam, partly due to synergistic GABA elevation from clobazam metabolite potentiation.[1][5]
Impact on Seizure Threshold and Mechanisms
Stiripentol raises seizure thresholds in genetic epilepsy models by enhancing phasic and tonic inhibition. It blocks voltage-gated sodium channels at higher doses (>100 μM), but GABAergic effects predominate at clinical levels (10-30 μM plasma).[4][6] No significant tolerance develops, unlike with benzodiazepines.
Potential Side Effects Tied to GABA Enhancement
Excessive GABAergic potentiation can cause drowsiness, ataxia, or hypotonia, especially in children. These occur in 20-30% of patients, resolving with dose adjustment.[5]
Comparisons with Other Antiepileptics